MILAN, May 25, 2023 /PRNewswire/ -- InSilicoTrials - a leading provider of artificial intelligence and simulation tools for drug and medical device development, and IBSA Group - one of the major players worldwide in the fields of Reproductive Medicine and hyaluronic acid-based products, have partnered to revolutionize drug development processes using in silico medicine.
At the heart of the collaboration between the two companies lies the in silico approach, which involves the use of various computational tools, such as computer simulations and mathematical models, to study biological systems at different levels, from the molecular to the cellular level and even at the organism level. In silico techniques can provide predictions about toxicity, efficacy, optimal dosing strategies and study design, and are currently employed by pharmaceutical companies to guide the different stages of the drug development process, from discovery through the nonclinical and clinical phases, drug registration as well as to leverage post-market real-world data.
Regulatory bodies such as the FDA have encouraged the adoption of in silico techniques, with the Modernization Act - FDAMA- 2.0 bill aiming to streamline drug regulation and bring safe medical products to market faster. The bill allows the use of alternatives methods to animal testing, such in silico testing, before or during the clinical trial phase. In silico studies have emerged as a new model of clinical trials, using algorithms to create computer models and provide clinical data without resorting to trials on living beings or in test tubes.
IBSA, which has made innovation one of its pillars, partnered with InSilicoTrials with the objective of evaluating the application of in silico medicine in specific therapeutic areas such as pain and inflammation, osteoarticular, and reproductive medicine. The collaboration between the two companies has the aim of reducing working times, lowering research costs, and implementing effective therapeutic solutions in less time, positively impacting healthcare expenditures.
InSilicoTrials' advanced computer simulations offer an innovative and cost-effective approach to drug development, generating valuable evidence for internal decision-making and regulatory submissions and reducing the need for costly and time-consuming clinical trials. This cutting-edge technology can increase the quality of life of millions of patients bringing innovative drugs to the market in a shorter time, together with personalized cures and new solutions for rare diseases.
For further news and updates, please visit: https://insilicotrials.com/ournews/
About InSilicoTrials
InSilicoTrials is a company that specializes in using artificial intelligence (AI) and simulations to improve drugs and medical device development.
The company built an ecosystem of more than 70 scientific collaborations, where computational models are developed with internationally recognized universities and research centers, offering access to the highest level of data security.
InSilicoTrials' goal is to help Pharmaceutical, MedTech companies and researchers develop new drugs & medical devices more efficiently and at a lower cost by reducing the need for traditional, time-consuming, and expensive clinical trials. With its cloud-based platform offering advanced M&S tools to perform in silico trials analyses, InSilicoTrials supports companies to integrate AI and simulation technology into their development workflows.
InSilicoTrials is currently working on four projects funded by the European Commission: In Silico World, SimCardioTest, Brainteaser & Disc4All.
About IBSA
IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company's 17 subsidiaries located in Europe, China, and the United States.
The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world's leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.
Photo - https://mma.prnewswire.com/media/2085427/InSilicoTrials.jpg
View original content:https://www.prnewswire.co.uk/news-releases/insilicotrials-and-ibsa-join-forces-to-innovate-clinical-trials-with-advanced-computer-modeling-301834502.html
